Anthem Biosciences Limited hereby informs the Exchange of the First Amendment to the Loan Agreement dated April 15, 2024, entered into with Neaonathem Lifesciences Private Limited (the Wholly Owned Subsidiary Company).
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anthem Biosciences has amended its loan agreement with its wholly-owned subsidiary Neoanthem Lifesciences Private Limited, signed on February 23, 2026. Under the First Amendment, the company now has the option to convert an additional Rs. 275 Crores of the loan into equity shares of Neoanthem, on top of the Rs. 100 Crores already converted in February 2025. The overall sanctioned financial assistance limit stands at Rs. 550 Crores, with Rs. 439.41 Crores outstanding as of the disclosure date. The loan is unsecured and interest-bearing, and the conversion will be at fair value based on a registered valuer's report at the time of allotment. The transaction was classified as a Material Related Party Transaction and approved by the Audit Committee, Board, and Shareholders.
No material impact on consolidated financials since Neoanthem is fully owned. On a standalone basis, the company's loan exposure to the subsidiary will reduce while its equity investment will increase by the same amount, effectively shifting the capital from debt to equity within the group.